Lipodystrophy and quality of life of HIV-infected persons

AIDS Reviews

Volumn 10, Issue 3, 2008, Pages 152-161

  Guaraldi, Giovanni ^a   Murri, Rita ^b   Orlando, Gabriella ^a   Squillace, Nicola ^a   Stentarelli, Chiara ^a   Zona, Stefano ^a   Garlassi, Elisa ^a   Martinez, Esteban ^c  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^b CATHOLIC UNIVERSITY   (Italy)

^c HOSPITAL CLÍNIC   (Spain)

Author keywords

Body changes; Body image; Health related quality of life; Lipodystrophy; Lipodystrophy case definition

Indexed keywords

ANTIRETROVIRUS AGENT; FILLER; POLYACRYLAMIDE; POLYLACTIC ACID;

BECK DEPRESSION INVENTORY; BODY FAT; BODY IMAGE; CLINICAL TRIAL; DEPRESSION; ESTHETICS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV ASSOCIATED LIPODYSTROPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN RELATION; LIPODYSTROPHY; MEDLINE; OUTCOME ASSESSMENT; PATIENT ATTITUDE; PATIENT COMPLIANCE; PATIENT SATISFACTION; PHYSICAL ATTRACTIVENESS; PLASTIC SURGERY; PSYCHOLOGICAL ASPECT; QUALITY OF LIFE; QUESTIONNAIRE; REVIEW; SELF CONCEPT; SELF EVALUATION; STIGMA; TISSUE TRANSPLANTATION;

ANTI-HIV AGENTS; BODY FAT DISTRIBUTION; BODY IMAGE; HIV INFECTIONS; HIV-ASSOCIATED LIPODYSTROPHY SYNDROME; HUMANS; QUALITY OF LIFE;

EID: 55049134099     PISSN: 11396121     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (38)

1. BHIVA guidelines for the treatment of HIV-infected adults with antiretroviral therapy HIV Med. 2006;7:478-503.
2. DHHS. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. http://aidsinfo.nih.gov/contentfiles/ Adultand-AdolescentGL.pdf 2007.
3. EACS. Guidelines on the prevention and management of metabolic disease in HIV. 2007.
4. Carr A, Samaras K, Burton S, et al. A syndrome of peripheral lipodystrophy, hyperlipidemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS. 1998;12:F51-8.
5. Lo J, Mulligan K, Tai V, Algren H, Schambelan M. Body shape changes in HIV-infected patients. J Acquir Immune Defic Syndr Hum Retrovirol. 1998;19:307-8.
6. Stricker R, Goldberg B. Fat accumulation and HIV-1 protease inhibitors. Lancet. 1998;352:1392.
7. Saint-Marc T. Partisani M, Poizot-Martin I, et al. A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analog therapy. AIDS. 1999;13:1659-67.
8. Keeton WP, Cash TF, Brown TA. Body image or body images? Comparative, multidimensional assessment among college students. J Pers Assess. 1990;54:213-30.
9. The psychology of physical appearance: Aesthetics, attributes and images. Body Images: Development, deviance and change. New York; Guiford P. 1990:51-79.
10. Cash T. The situational inventory of body-image dysphora: psychometric evidence and development of a short form. Int J Eat Disord. 2002;32:362-6.
11. Cash T, Green G. Body weight and body image among college women: perception, cognition, and affect. J Pers Assess. 1986; 50:290-301.
12. Freedman R. Cognitive-behavioral perspectives and body image change. In TF Cash & Pruzinsky (Eds.), Body images: Development, deviance and change. New York. Guilford. 1990: 272-95.
13. Testa M, Simonson D. Assessment of QoL outcomes. N Engl J Med. 1996;334:835-40.
14. Allebeck P, Hallberg D, Espmark S. Body Image: an apparatus for measuring disturbances in estimation of size and shape. J Psychosom Res. 1976;20:583-9.
15. Guaraldi G, Orlando G, Murri R, et al. Quality of life and body image in the assessment of psychological impact of lipodystrophy: validation of the Italian version of assessment of body change and distress questionnaire. Qual Life Res. 2006;15:173-8.
16. Cash T, Phillips K, Santos M, Hrabosky J. Measuring "negative body image": validation of the Body Image Disturbance Questionnaire in a nonclinical population. Body Image. 2004;1:363-72.
17. Paton N, Earnest A, Ng Y, Karim F, Aboulhab J. Lipodystrophy in a cohort of HIV-infected Asian patients: prevalence, associated factors, and psychological impact. Clin Infect Dis. 2002;35: 1244-9.
18. Oette M, Juretzko P, Kroidl A, et al. Lipodystrophy syndrome and self-assessment of well-being and physical appearance in HIV-positive patients. AIDS Patient Care STDS. 2002;16:413-7.
19. Power R, Tate H, McGill S, Taylor C. A qualitative study of the psychosocial implications of lipodystrophy syndrome on HIV-positive individuals. Sex Transm Infect. 2003:79:137-41.
20. Collins E, Wagner C, Walmsley S. Psychosocial impact of the lipodystrophy syndrome in HIV infection. AIDS Read. 2000; 10:546-50.
21. Blanch J, Rousaud A, Martinez E, et al. Impact of lipodystrophy on the QoL of HIV-1-infected patients. J Acquir Immune Defic Syndr. 2002;31:404-7.
22. Blanch J, Rousaud A, Martinez E, et al. Factors associated with severe impact of lipodystrophy on the QoL of patients infected with HIV-1. Clin Infect Dis. 2004;38:1464-70.
23. Burgoyne R, Collins E, Wagner C, et al. The relationship between lipodystrophy-associated body changes and measures of QoL and mental health for HIV-positive adults. Qual Life Res. 2005; 14:981-90.
24. Liu C, Johnson L. Ostrow D, Silvestre A, Visscher B, Jacobson L. Predictors for lower QoL in the HAART era among HIV-infected men. J Acquir Immune Defic Syndr. 2006;42:470-7.
25. Guaraldi G, Murri R, Orlando G, et al. Severity of lipodystrophy is associated with decreased health-related quality of life. AIDS Patient Care STDS. 2008;22:577-85.
26. Marin A. Casado JL, Aranzabal L, et al. Validation of a specific questionnaire on psychological and social repercussions of the lipodystrophy syndrome in HIV-infected patients. Qual Life Res. 2006;15:767-75.
27. Steel J, Landsittel D, Calhoun B, Wieand S, Kingsley L. Effects of lipodystrophy on QoL and depression in HIV-infected men on HAART. AIDS Patient Care STDS. 2006;20:565-75.
28. Dukers N, Stolte IG, Albrecht N, Coutinho R, de Wit J. The impact of experiencing lipodystrophy on the sexual behavior and well-being among HIV-infected homosexual men. AIDS. 2001;15:812-3.
29. Guaraldi G, Luzi K. Murri R, et al. Sexual dysfunction in HIV-infected men: role of antiretroviral therapy, hypogonadism and lipodystrophy, Antivir Ther. 2007;12:1059-65.
30. Guaraldi G, Murri R, Orlando G, et al. Morphologic alterations in HIV-infected people with podystrophy are associated with good adherence to HAART. HIV Clin Trials. 2003;4:99-106.
31. Ammassari A. Antinori A. Cozzi-Leph A, et al. Relationship between HAART adherence and adipose tissue alterations. J Acquir Immune Defic Syndr. 2002;31(Suppl 3):S140-4.
32. Guaraldi G, Orlando G, De Fazio D, et al. Comparison of three different interventions for the correction of HIV-associated facial lipoatrophy: a prospective study. Antivir Ther. 2005;10:753-9.
33. Negredo E, Higueras C, Adell X, et al. Reconstructive treatment for anti retroviral-associated facial lipoatrophy: a prospective study comparing autologous fat and synthetic substances. AIDS Patient Care STDS. 2006;20:829-37.
34. Guaraldi G, De Fazio D, Orlando G, et al. Facial lipohypertrophy in HIV-infected subjects who underwent autologous fat tissue transplantation. Clin Infect Dis. 2005;40:el3-5.
35. Orlando G, Guaraldi G. De Fazio D. et al. Long term psychometric outcomes of facial lipoatrophy therapy. AIDS Patient Care STDS. 2007;21:833-42.
36. Beck A, Steer R. Internal consistencies of the original and revised Beck Depression Inventory. J Clin Psychol, 1984;40:1365-7.
37. Brown C, Schulberg H. Diagnosis and treatment of depression in primary medical care practice: the application of research findings to clinical practice, J Clin Psychol. 1998;54:303-14.
38. Loutfy M, Raboud J, Antoniou T, et al. Immediate versus delayed poly-alkylimide gel injections to correct facial lipoatrophy in HIV-positive patients. AIDS. 2007;21:1147-55.